These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11382563)

  • 1. The treatment of hypertension in patients with diabetes.
    Smith A
    Nurs Clin North Am; 2001 Jun; 36(2):273-89, vii. PubMed ID: 11382563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of blood pressure in patients with diabetes.
    Grossman E; Messerli FH
    Am J Hypertens; 2011 Aug; 24(8):863-75. PubMed ID: 21525967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension: just the facts.
    Sharp K
    Clin J Oncol Nurs; 2006 Dec; 10(6):727-9. PubMed ID: 17193939
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
    Jerums G; MacIsaac RJ
    Treat Endocrinol; 2002; 1(3):163-73. PubMed ID: 15799209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of diabetes mellitus in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2006; 27(2):77-82. PubMed ID: 16638476
    [No Abstract]   [Full Text] [Related]  

  • 7. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.
    Mogensen CE
    J Intern Med; 2003 Jul; 254(1):45-66. PubMed ID: 12823642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-pressure control preserves renal function.
    Frankel DH
    Lancet; 1998 May; 351(9115):1562. PubMed ID: 10326550
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of diabetes mellitus associated with hypertension].
    Katayama H
    Nihon Naika Gakkai Zasshi; 1996 Apr; 85(4):514-8. PubMed ID: 8708466
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic nephropathy.
    Castellino P; Tuttle KR; DeFronzo RA
    Curr Ther Endocrinol Metab; 1994; 5():426-36. PubMed ID: 7704768
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of obesity hypertension and diabetes syndrome.
    Zanella MT; Kohlmann O; Ribeiro AB
    Hypertension; 2001 Sep; 38(3 Pt 2):705-8. PubMed ID: 11566961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure, diabetes and diabetic nephropathy.
    Chantrel F; Moulin B; Hannedouche T
    Diabetes Metab; 2000 Jul; 26 Suppl 4():37-44. PubMed ID: 10922972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.
    Vijan S; Hayward RA
    Ann Intern Med; 2003 Apr; 138(7):593-602. PubMed ID: 12667032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
    Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
    Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)].
    Pérez Blanco FJ; Manzanares L; Moreno G; Cabello MJ
    An Med Interna; 1996 Apr; 13(4):193-7. PubMed ID: 8688481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.